RBC Capital Comments on Regeneron (REGN) Following 'Unexpectedly Cautious' Adcom
Tweet Send to a Friend
RBC Capital maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN) with a price target of $543. Yesterday an FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
